Repare Therapeutics IncNASDAQ:RPTX
- LAST PRICE3.5500
- TODAY'S CHANGE (%)-0.0200 (-0.5602%)
- Bid / Lots3.5000/ 1
- Ask / Lots3.6800/ 1
- Open / Previous Close3.5700 / 3.5700
- Day Range
- 52 Week Range
- Volume113,902
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPTX |
|---|---|---|
| 09:32 ET | 796 | 3.57 |
| 09:34 ET | 300 | 3.6066 |
| 09:36 ET | 1020 | 3.56 |
| 09:38 ET | 323 | 3.5513 |
| 09:39 ET | 1800 | 3.5299 |
| 09:41 ET | 2298 | 3.51 |
| 09:52 ET | 1100 | 3.53 |
| 09:56 ET | 206 | 3.5113 |
| 09:59 ET | 209 | 3.5112 |
| 10:01 ET | 534 | 3.53 |
| 10:10 ET | 100 | 3.52 |
| 10:14 ET | 150 | 3.51 |
| 10:21 ET | 100 | 3.5224 |
| 10:37 ET | 1000 | 3.52 |
| 10:39 ET | 6496 | 3.51 |
| 10:42 ET | 1400 | 3.51 |
| 10:44 ET | 100 | 3.51 |
| 10:48 ET | 1600 | 3.49 |
| 10:50 ET | 300 | 3.5086 |
| 10:51 ET | 522 | 3.4931 |
| 10:53 ET | 100 | 3.5102 |
| 10:57 ET | 2936 | 3.49 |
| 11:00 ET | 800 | 3.51 |
| 11:02 ET | 100 | 3.52 |
| 11:04 ET | 6389 | 3.505 |
| 11:11 ET | 100 | 3.49 |
| 11:18 ET | 500 | 3.49 |
| 11:22 ET | 2573 | 3.48 |
| 11:24 ET | 4532 | 3.485 |
| 11:26 ET | 500 | 3.485 |
| 11:27 ET | 100 | 3.4805 |
| 11:31 ET | 100 | 3.48 |
| 11:33 ET | 691 | 3.48 |
| 11:36 ET | 200 | 3.47 |
| 11:49 ET | 200 | 3.475 |
| 11:51 ET | 2313 | 3.48 |
| 11:54 ET | 834 | 3.5 |
| 11:56 ET | 2100 | 3.5 |
| 12:00 ET | 300 | 3.51 |
| 12:02 ET | 300 | 3.52 |
| 12:07 ET | 500 | 3.53 |
| 12:09 ET | 2000 | 3.52 |
| 12:18 ET | 1533 | 3.5634 |
| 12:20 ET | 200 | 3.53 |
| 12:23 ET | 995 | 3.57 |
| 12:30 ET | 200 | 3.56 |
| 12:32 ET | 875 | 3.55 |
| 12:56 ET | 200 | 3.56 |
| 12:57 ET | 400 | 3.56 |
| 12:59 ET | 300 | 3.59 |
| 01:17 ET | 300 | 3.6 |
| 01:19 ET | 100 | 3.58 |
| 01:21 ET | 977 | 3.6187 |
| 01:24 ET | 200 | 3.6 |
| 01:28 ET | 100 | 3.6 |
| 01:30 ET | 10500 | 3.51 |
| 01:32 ET | 300 | 3.53 |
| 01:35 ET | 100 | 3.52 |
| 01:39 ET | 444 | 3.5498 |
| 01:44 ET | 100 | 3.56 |
| 01:46 ET | 100 | 3.52 |
| 01:51 ET | 200 | 3.55 |
| 01:53 ET | 700 | 3.52 |
| 01:57 ET | 100 | 3.52 |
| 02:00 ET | 910 | 3.53 |
| 02:02 ET | 363 | 3.53 |
| 02:09 ET | 100 | 3.51 |
| 02:13 ET | 100 | 3.51 |
| 02:20 ET | 100 | 3.51 |
| 02:22 ET | 200 | 3.52 |
| 02:27 ET | 6434 | 3.5 |
| 02:31 ET | 100 | 3.515 |
| 02:33 ET | 300 | 3.5 |
| 02:36 ET | 600 | 3.51 |
| 02:44 ET | 200 | 3.51 |
| 02:45 ET | 300 | 3.5 |
| 02:51 ET | 200 | 3.52 |
| 03:00 ET | 100 | 3.51 |
| 03:07 ET | 684 | 3.5001 |
| 03:09 ET | 100 | 3.51 |
| 03:12 ET | 600 | 3.502 |
| 03:14 ET | 100 | 3.52 |
| 03:16 ET | 800 | 3.48 |
| 03:18 ET | 100 | 3.48 |
| 03:20 ET | 100 | 3.52 |
| 03:21 ET | 100 | 3.5 |
| 03:23 ET | 400 | 3.49 |
| 03:25 ET | 500 | 3.4913 |
| 03:27 ET | 191 | 3.5 |
| 03:34 ET | 100 | 3.53 |
| 03:36 ET | 200 | 3.5046 |
| 03:39 ET | 100 | 3.515 |
| 03:41 ET | 100 | 3.5 |
| 03:45 ET | 818 | 3.54 |
| 03:48 ET | 100 | 3.55 |
| 03:50 ET | 200 | 3.54 |
| 03:52 ET | 100 | 3.55 |
| 03:54 ET | 300 | 3.54 |
| 03:56 ET | 2464 | 3.53 |
| 03:57 ET | 302 | 3.54 |
| 03:59 ET | 7319 | 3.55 |
May 8, 2024
DJ Repare Therapeutics Shares Rise 17% After 1Q Earnings, Revenue Beats, from 12:34PM ET on Wednesday May 08, 2024 by Dow Jones
12:34PM ET on Wednesday May 08, 2024 by Dow Jones
May 7, 2024
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones*DJ Repare Therapeutics 1Q EPS 30c >RPTX, from 4:05PM ET on Tuesday May 07, 2024 by Dow Jones
4:05PM ET on Tuesday May 07, 2024 by Dow Jones
Apr 30, 2024
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition, from 7:05AM ET on Tuesday Apr 30, 2024 by Dow Jones
7:05AM ET on Tuesday Apr 30, 2024 by Dow JonesDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition, from 7:05AM ET on Tuesday Apr 30, 2024 by Dow Jones
7:05AM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Repare Therapeutics Inc | 151.5M | -3.2x | --- |
AVITA Medical Inc | 211.6M | -4.5x | --- |
Precision BioSciences Inc | 83.7M | -2.2x | --- |
Genfit SA | 186.8M | -6.0x | --- |
Champions Oncology Inc | 65.4M | -6.6x | --- |
Innate Pharma SA | 205.6M | -25.2x | --- |
Company Information
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Contact Information
- Headquarters
- 7210 Frederick-Banting, Suite 100ST-LAURENT, QC, Canada H4S 2A1
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Thomas Civik
- President, Chief Executive Officer, Director
- Lloyd Segal
- Chief Financial Officer, Executive Vice President
- Steve Forte
- Executive Vice President, Chief Scientific Officer
- Michael Zinda
- Executive Vice President, Chief Medical Officer
- Maria Koehler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $151.5M |
|---|---|
Revenue (TTM) | $97.9M |
Shares Outstanding | 42.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-1.10 |
Book Value | $5.03 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -72.27% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
